$227 Million is the total value of MPM ASSET MANAGEMENT LLC's 5 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HARP | Harpoon Therapeutics, Inc. | $66,916,000 | +8.3% | 4,524,425 | 0.0% | 29.45% | +11.4% | |
| TCRR | TCR2 Therapeutics, Inc. | $57,846,000 | -5.0% | 4,050,865 | 0.0% | 25.46% | -2.3% | |
| RYTM | Sell | Rhythm Pharmaceuticals, Inc. | $54,955,000 | -17.2% | 2,393,497 | -22.2% | 24.19% | -14.9% |
| CHMA | Chiasma, Inc. | $28,452,000 | +0.2% | 5,736,296 | 0.0% | 12.52% | +3.0% | |
| SNDX | Syndax Pharmaceuticals, Inc. | $19,041,000 | +17.5% | 2,168,691 | 0.0% | 8.38% | +20.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.